The ImmunoPeCa study (PIs: Flatmark, Dueland) exploits the MOC31PE immunotoxin as targeted therapy for EpCAM positive peritoneal carcinomatosis from CRC (PC-CRC). MOC31PE binds to the EpCAM surface protein, which is highly expressed by epithelial tumour cells, and has shown rapid cytotoxicity, a distinct mechanism of action, and selectivity via the tumour-associated adhesion molecule EpCAM [Flatmark et al., 2013]. The trial started accrual in August of 2014 and was conducted at OUS NRH as national provider for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for PC-CRC. MOC31PE was administered following the established therapeutic procedures. Pharmacokinetics analysis and treatment outcome will be evaluated in a phase 1 and 2 of the study design.
Flatmark, K., Guldvik, I.J., Svensson, H., Fleten, K.G., Flørenes, V.A., Reed, W., Giercksky, K.E., Fodstad, Ø. and Andersson, Y. (2013). Immunotoxin targetting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. International Journal of Cancer, Vol. 133(6), pp. 1497-1506. (Link)
Frøysnes, I.S., Larsen S.G., Spasojevic, M., Dueland, S., and Flatmark, K. (2016). Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: factors and oncologic outcome in a national patient cohort. Journal of Surgical Oncology, Vol. 114(2), pp. 222-227. (Link)
Frøysnes, I.S., Andersson, Y., Larsen, S.G., Davidson, B., Øien, J.T., Olsen, K.H., Giercksky, K.E., Julsrud, L., Fødstad, Ø., Dueland, S., and Flatmark, K. (2017). Novel treatment with intraperitoneal MOC31PE Immunotoxin in colorectal peritoneal metastasis: Results from the ImmunoPeCa Phase 1 trial. Annals of Surgical Oncology, Vol. 24(7), pp. 1916-1922. (Link)